NSE: RUBICON · 3 November 2026
- Rubicon Research has risen 10.31% over 3 trading sessions; today's move is +3.15%.
- Rubicon Research announced the outcome of an unannounced USFDA inspection of its manufacturing facility in Ambernath, Maharashtra, conducted from October 21 to October 29, 2026. The inspection resulted in a Form 483 containing three observations for system improvement and two related to a product application under review, with the company noting all five are procedural and do not involve data integrity.
- Trading volume was 1.03 times the 20-day average daily volume.
Rubicon Research share price: 10.31% rise over 3 trading sessions
Rubicon Research Ltd. shares moved higher today, gaining 3.15% to settle at ₹1,720.00. The stock opened at ₹1,694.90 and moved within a intraday range of ₹1,674.10 and ₹1,32.90.
The broader market and sectoral trend provided a supportive backdrop for today's trading session. The Nifty benchmark advanced by 1.58%, while the Nifty Pharma sector index posted a modest gain of 0.42%. Rubicon Research outperformed both the broader market index and its sectoral gauge, extending its positive momentum following a 5-day return of 13.94%.
Recent company disclosures highlight ongoing regulatory evaluations across the company's manufacturing network, including an unannounced USFDA inspection at the Ambernath facility that concluded with procedural observations. While these updates provide important operational context regarding facility statuses, there is no direct evidence linking them as the immediate catalyst for today's price action.
1.93 lakh shares traded by 3 November 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 1.87 lakh shares (1.03 times). The five-day average daily volume was 1.82 lakh shares. Separately, the NSE report for 2 November 2026 showed 1.94 lakh shares delivered, representing 52.20% of that day’s traded volume. The same report recorded 41,769 trades.
The stock's 3.15% gain occurred alongside above-average cash volume and positive short-term momentum following strong recent returns, though no single same-day announcement triggered the move.
Latest Company Developments
Rubicon Research announced the outcome of an unannounced USFDA inspection of its manufacturing facility in Ambernath, Maharashtra, conducted from October 21 to October 29, 2026. The inspection resulted in a Form 483 containing three observations for system improvement and two related to a product application under review, with the company noting all five are procedural and do not involve data integrity.
Regulatory compliance and inspection outcomes at key manufacturing sites are vital for maintaining product approvals and supporting future commercial pipelines in regulated markets.
The company reported that the USFDA conducted an unannounced inspection of its manufacturing facility in Satara, Maharashtra, from October 5 to October 9, 2026. The inspection concluded with a single procedural observation that did not involve data integrity, marking a continuation of regulatory audits across the company's operational footprint.
Successful navigation of unannounced regulatory inspections validates manufacturing standards and reinforces operational readiness across key production sites.
Rubicon Research Limited has submitted to the Exchange, the financial results for the quarter ended Jun 30, 2026.
'Corrigendum to the Integrated Annual Report for the financial year 2025-26 '.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.78% on 30 September 2026. This compares with 7.23% on 30 June 2026, a change of +6.55 percentage points.
The filing reported 20 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming financial results and board meeting scheduled for November 5, 2026.
- Regulatory updates regarding EIR issuance and responses for the Ambernath and Satara manufacturing facilities.
- Execution progress on the company's specialty products and complex generics pipeline.
- Cash volume and delivery trends relative to the 20-day average volume.
More Rubicon Research news and dated analysis →
Frequently Asked Questions
What is the latest Rubicon Research company news?
Rubicon Research announced the outcome of an unannounced USFDA inspection of its manufacturing facility in Ambernath, Maharashtra, conducted from October 21 to October 29, 2026. The inspection resulted in a Form 483 containing three observations for system improvement and two related to a product application under review, with the company noting all five are procedural and do not involve data integrity.
How strong was Rubicon Research’s trading volume?
1.93 lakh shares traded, 1.03 times the 20-day average daily volume. The price and volume data are dated 3 November 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.